Lambster2
$MDWD
MediWound Ltd. (NASDAQ: MDWD)
Buy (1)
Price Target: $25.00
EscharEx Approaching Its VALUE Inflection; A Potential Wound-Care Disruptor
THE TD COWEN INSIGHT
We see an increasingly attractive setup into the Phase 3 VALUE interim analysis. Positive EscharEx data could validate its differentiated 4-5 day debridement profile, challenge Santyl’s entrenched ~$400M franchise, unlock a potentially much larger $1B+ VLU opportunity, and generate substantial strategic interest. Reiterate Buy.
2
